Last updated: September 24, 2026
Darifenacin is an extended-release antimuscarinic used for overactive bladder. Its commercial opportunity is primarily generic and formulation-driven: manufacturers can compete through lower-cost extended-release tablets, improved swallowing characteristics, differentiated packaging, global registrations, and supply-chain efficiency. The central technical challenge is maintaining controlled release of darifenacin hydrobromide while limiting dose dumping, food effects, and variability caused by excipient or process changes.
What is darifenacin and how is it formulated?
Darifenacin hydrobromide is the active pharmaceutical ingredient in the once-daily extended-release product Enablex. The FDA-approved strengths are 7.5 mg and 15 mg, administered once daily for urge urinary incontinence, urgency, and increased urinary frequency associated with overactive bladder.[1]
| Attribute |
Darifenacin |
| Active ingredient |
Darifenacin hydrobromide |
| Therapeutic class |
Muscarinic M3 receptor antagonist |
| Primary indication |
Overactive bladder |
| Dosage form |
Extended-release oral tablet |
| Approved strengths |
7.5 mg and 15 mg |
| Dosing frequency |
Once daily |
| Key metabolism |
CYP2D6 and CYP3A4 |
| Main formulation requirement |
Controlled release over approximately 24 hours |
| Principal commercial route |
Generic extended-release tablets |
| Biosimilar relevance |
None; darifenacin is a small molecule |
The reference product uses a matrix-based extended-release tablet. Published labeling identifies excipients including hypromellose, dibasic calcium phosphate, magnesium stearate, polyethylene glycol, talc, and titanium dioxide.[1] Exact excipient levels, particle-size distributions, granulation conditions, coating parameters, and compression profiles can remain commercially important even when the broad excipient list is no longer novel.
What excipients are most important in darifenacin extended-release tablets?
The highest-value excipients are release-controlling polymers, diluents, lubricants, and film-coating materials.
Hypromellose and other hydrophilic polymers
Hypromellose, or HPMC, is the principal excipient platform for a hydrophilic matrix. After hydration, HPMC forms a gel layer that controls water penetration and drug diffusion. Polymer viscosity grade, substitution type, particle size, and loading level affect:
- Initial drug release
- Gel strength
- Tablet erosion
- Release duration
- Sensitivity to agitation
- Food-related changes in dissolution
A generic manufacturer can use HPMC grades from multiple suppliers, but the formulation must demonstrate equivalent release behavior across the full dissolution profile. A substitution that reduces polymer cost can create regulatory risk if it changes early release or causes faster release at higher agitation speeds.
Dibasic calcium phosphate and other diluents
Dibasic calcium phosphate can provide tablet mass, improve flow, and support compression. It is less water-soluble than common alternatives such as lactose or mannitol. That property can influence matrix hydration and porosity.
Potential alternatives include microcrystalline cellulose, lactose, mannitol, and spray-dried composite diluents. Each alternative changes tablet hardness, friability, disintegration behavior, and release kinetics. Direct substitution is therefore unlikely to be a low-risk change in a controlled-release product.
Magnesium stearate
Magnesium stearate reduces tooling friction and prevents tablet sticking. Excessive lubrication can create hydrophobic particle coatings that slow hydration and alter release. Blending time, lubricant concentration, and shear history should be treated as critical process variables.
A manufacturer seeking higher throughput may need to balance shorter lubrication time against content uniformity and tablet ejection force. Continuous manufacturing may offer a commercial advantage, but it requires strong control of blend segregation and polymer distribution.
Film-coating excipients
Polyethylene glycol, talc, titanium dioxide, and related coating components support tablet appearance, mechanical protection, and swallowing. The film coat generally is not the primary release-controlling element in the reference product, but coat weight and curing can affect moisture transfer and tablet handling.
Colorant changes can provide a practical product differentiation strategy, but they add limited therapeutic value. The stronger commercial opportunity is a robust, low-defect coating process that reduces rejects and improves packaging stability.
What excipient strategies can differentiate generic darifenacin?
A generic manufacturer has four commercially realistic formulation strategies.
Standard hydrophilic matrix
The lowest-risk route is a conventional HPMC matrix using excipients with established regulatory histories. This approach minimizes novel excipient concerns and supports an abbreviated new drug application, or ANDA, when bioequivalence and dissolution requirements are met.
The weakness is limited differentiation. Multiple manufacturers can pursue similar formulations, creating price pressure after launch.
Low-weight matrix tablet
A higher polymer efficiency formulation can reduce tablet size while retaining 24-hour release. This is relevant because patients with overactive bladder are often older adults who may have difficulty swallowing tablets.
The formulation objective is not simply a smaller tablet. It must preserve dose uniformity, mechanical strength, release control, and stability. High-polymer systems can increase tablet bulk and may slow manufacturing.
Multiparticulate or coated-pellet system
Pellets or minitablets can distribute drug across multiple units and reduce sensitivity to localized tablet defects. A multiparticulate product may also support sprinkle or capsule delivery, although that would create a dosage-form change and a more complex regulatory pathway.
The main barriers are coating uniformity, equipment cost, capsule or sachet packaging, and scale-up. This strategy has greater product differentiation potential than a conventional matrix tablet but requires stronger development evidence.
Osmotic or high-performance membrane system
An osmotic system can provide highly controlled release and reduce dependence on matrix erosion. It also requires specialized manufacturing, membrane coating, laser drilling or equivalent control, and more extensive process validation.
For darifenacin, this approach is more likely to support a differentiated product or a proprietary reformulation than a low-cost first-wave generic. The additional manufacturing cost may not be justified unless the product provides a clear adherence or pharmacokinetic benefit.
What formulation patents protect darifenacin products?
Darifenacin’s historic intellectual-property position has centered on the active compound, pharmaceutical compositions, extended-release dosage forms, and methods of treating urinary disorders. The original branded product is no longer protected by the type of market exclusivity associated with a newly launched medicine.
For current commercial planning, the relevant IP questions are narrower:
- Whether any enforceable U.S. patent remains listed for a specific extended-release product.
- Whether a generic applicant can submit a Paragraph IV certification against a listed patent.
- Whether a proposed formulation falls within composition, release-profile, or method-of-use claims.
- Whether manufacturing-process claims create a practical barrier outside the Orange Book.
- Whether country-specific patents remain active in Europe, Japan, China, or other markets.
A formulation patent can remain commercially relevant even when the basic compound patent has expired. Claims directed to polymer ratios, coating structures, particle populations, or specific dissolution profiles are the most relevant categories for a controlled-release darifenacin product. Process patents and supplier know-how are less visible in regulatory databases but can affect cost and scale-up.
When did darifenacin lose exclusivity?
Darifenacin lost the commercial position associated with the Enablex brand after expiration of its core exclusivity period and subsequent generic entry. The product was approved in the United States in 2004, and the first generic competition emerged years later through abbreviated approval pathways.[1,2]
The practical exclusivity timeline is:
| Period |
Commercial position |
| 2004 |
FDA approval of Enablex extended-release tablets |
| Post-approval period |
Brand-led market with patent and regulatory exclusivity |
| After core patent expiry |
ANDA-based generic competition became possible |
| Current market |
Mature small-molecule generic opportunity |
| Current differentiation |
Formulation quality, price, supply reliability, and market access |
Exact patent expiry must be assessed patent by patent because U.S. patent-term adjustment, pediatric extensions, terminal disclaimers, and Orange Book listing history can change the effective date. For a launch decision, the controlling evidence is the current FDA Orange Book record and the relevant patent documents, not the brand approval date alone.[2]
What is the FDA regulatory status and Orange Book position?
Darifenacin is an FDA-approved small-molecule prescription drug. Generic manufacturers generally pursue an ANDA referencing the approved extended-release product. The principal regulatory issues are bioequivalence, comparative dissolution, stability, manufacturing controls, and labeling consistency.[3]
The Orange Book is important because it identifies approved reference products, therapeutic-equivalence ratings, and patents or exclusivity information relevant to listed products.[2] A generic applicant may use Paragraph III certification when a listed patent remains active or Paragraph IV certification when it asserts that the patent is invalid, unenforceable, or not infringed.
For darifenacin, regulatory risk is more likely to arise from extended-release equivalence than from active-ingredient chemistry. A tablet can meet conventional pharmacokinetic targets while showing a materially different dissolution profile under certain conditions. FDA’s modified-release guidance supports evaluation across multiple media, agitation conditions, and time points.[3]
What generic entry risks exist for darifenacin?
The principal risks are technical rather than clinical.
Dose dumping
Rapid release can increase systemic exposure and potentially worsen anticholinergic adverse effects. The risk is evaluated through dissolution testing and pharmacokinetic studies.
Food effects
Changes in gastric contents can alter hydration, erosion, or transit of a matrix tablet. A formulation that performs well under fasting conditions may require additional assessment under fed conditions.
CYP-mediated exposure
Darifenacin is metabolized by CYP2D6 and CYP3A4. Strong CYP3A4 inhibitors can increase exposure, while patient-level CYP2D6 differences can affect pharmacokinetics.[1] Excipients do not usually change this metabolic pathway directly, but release-rate changes can alter peak exposure.
Tablet size and adherence
A large matrix tablet may reduce acceptability among older patients. A smaller tablet, capsule-based multiparticulate product, or easier-to-swallow formulation could command a modest commercial advantage if it remains substitutable or obtains a distinct regulatory position.
Supplier and change-control risk
HPMC viscosity variation, magnesium stearate grade, and diluent moisture can affect release. Dual sourcing is commercially attractive but requires comparability work before implementation.
How strong is the darifenacin patent estate?
The historic estate is no longer a major barrier to generic participation. The more relevant protection resides in product-specific formulation claims, process know-how, trademarks, and commercial execution.
| IP category |
Current commercial significance |
| Core compound patents |
Low after expiration |
| Basic composition patents |
Low to moderate, depending on jurisdiction and claim status |
| Extended-release formulation patents |
Potentially relevant for specific products |
| Method-of-use patents |
Limited value where indication claims have expired or are difficult to enforce |
| Manufacturing patents |
Relevant to cost and scale, often outside Orange Book visibility |
| Trademarks |
Brand recognition, but limited protection against generic substitution |
| Trade secrets |
Meaningful for polymer selection, process windows, and coating performance |
The estate should therefore be assessed as a mature, execution-sensitive portfolio rather than a high-barrier innovator franchise.
Which companies are positioned to compete in darifenacin?
Competition is likely to involve established generic manufacturers with experience in modified-release tablets. The relevant capabilities include:
- ANDA development and Paragraph IV strategy
- Controlled-release formulation development
- Access to qualified HPMC and coating suppliers
- High-volume tablet compression
- Pharmacokinetic bioequivalence execution
- Retail, specialty, and government-market contracting
- Multi-country regulatory filing capability
The most competitive manufacturers will be those that can produce a stable extended-release tablet at low cost while maintaining supply continuity. Because darifenacin is a mature molecule, commercial success is more likely to come from manufacturing reliability and portfolio bundling than from premium pricing.
What licensing deals and commercial opportunities exist?
Darifenacin offers several licensing opportunities:
- Regional rights for generic extended-release tablets in markets where competition remains limited.
- Technology licensing for smaller tablets, multiparticulates, or alternative controlled-release systems.
- Contract development and manufacturing for companies lacking modified-release capabilities.
- Co-development of combination products for overactive bladder.
- Private-label supply to pharmacy chains and government procurement organizations.
- Reformulation licensing for patients with swallowing difficulties.
The strongest opportunity is a low-cost, globally registrable extended-release platform. A premium reformulation would need a clear benefit, such as improved swallowing, reduced tablet burden, or a validated adherence advantage.
How does darifenacin compare with competing overactive-bladder drugs?
| Drug |
Release opportunity |
Main competitive issue |
| Darifenacin |
Extended-release tablet and multiparticulate reformulation |
Mature generic pricing |
| Oxybutynin |
Immediate-release, extended-release, transdermal, and topical products |
Broad dosage-form competition |
| Tolterodine |
Immediate-release and extended-release products |
Established generic base |
| Solifenacin |
Once-daily tablet |
Strong brand and generic competition |
| Trospium |
Immediate-release and extended-release products |
Different food and administration requirements |
| Mirabegron |
Extended-release beta-3 agonist |
Non-antimuscarinic positioning and higher product differentiation |
Darifenacin’s M3 selectivity can support physician positioning, but excipient-based differentiation will not overcome a large price gap unless it produces a measurable usability or adherence benefit.
Key Takeaways
- Darifenacin is a mature small-molecule opportunity centered on extended-release generic tablets.
- HPMC selection, polymer loading, lubrication, moisture control, and coating process parameters are the core excipient variables.
- The safest generic strategy is a conventional hydrophilic matrix using established excipients.
- Smaller tablets and multiparticulate systems offer greater differentiation but carry higher development and manufacturing costs.
- The main regulatory risk is proving extended-release equivalence across dissolution and pharmacokinetic conditions.
- Core compound exclusivity is no longer the principal barrier; formulation claims, manufacturing know-how, and supply reliability matter more.
- Biosimilar strategy is irrelevant because darifenacin is not a biologic.
- Licensing opportunities are strongest in regional generic supply, modified-release technology, contract manufacturing, and patient-friendly dosage forms.
FAQs
Is darifenacin an immediate-release or extended-release drug?
The FDA-approved Enablex product is an extended-release tablet taken once daily. The release system is designed to maintain exposure over approximately 24 hours.[1]
Which excipient controls darifenacin release?
Hypromellose is the principal release-controlling excipient in the conventional hydrophilic matrix formulation. Its viscosity grade, concentration, particle size, and processing conditions affect the release profile.
Can darifenacin be developed as an orally disintegrating tablet?
Yes, but an orally disintegrating dosage form would require careful control of taste, tablet strength, drug loading, and release performance. A conventional immediate-disintegration platform may conflict with the need for extended release.
Is there biosimilar competition for darifenacin?
No. Darifenacin is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, principally ANDAs in the United States, rather than biosimilar applications.
What is the most attractive commercial reformulation?
A smaller, easier-to-swallow extended-release tablet is the most practical reformulation opportunity. Multiparticulate delivery may offer stronger differentiation but requires greater investment in coating, packaging, process validation, and regulatory support.
References
-
U.S. Food and Drug Administration. (2011). Enablex (darifenacin hydrobromide) extended-release tablets prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (1997). Guidance for industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. FDA.
-
U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.
